A phase I clinical trial of CRISPR-Cas9 PD-1-edited T cells in non-small-cell lung cancer demonstrates that the disruption of PD-1 on T cells generally induced grade 1 or 2 adverse events, and the most frequent events were lymphopenia, fatigue, leukopenia, fever, arthralgia, and skin rash. The gene discussed is PDCD1; the disease is Skin rash.